References

• Bertini S, Fareed J, Madaschi L, et al. Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential. Clin Appl Thromb Hemost. 2017; doi: 10.1177/1076029616685430
  http://journals.sagepub.com/doi/abs/10.1177/1076029616685430?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
• Nguyen T-H, Greinacher A, Delcea M. Quantitative description of thermodynamic and kinetic properties of the platelet factor 4/heparin bonds. Nanoscale. 2015; 7:10130-10139
  http://pubs.rsc.org/en/Content/ArticleLanding/2015/NR/C5NR02132D#!divAbstract
• Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3, and platelet factor 4. Blood. 2014;123(20):3166–74.
  http://www.bloodjournal.org/content/123/20/3166.long?sso-checked=true
• Block S, Greinacher A, Helm CA, et al. Characterization of bonds formed between platelet factor 4 and negatively charged drugs using single molecule force spectroscopy. Soft matter. 2014;10(16):2775–84.
  http://pubs.rsc.org/en/Content/ArticleLanding/2014/SM/c3sm52609g#!divAbstract
• Schulze A, Jensch I, Krauel K, et al. New insights in heparin-induced thrombocytopenia by the use of fluid-phase assays to detect specifically platelet factor 4/heparin complex antibodies and antibody-secreting cells. Thrombosis research. 2014;134(1):174–81.
  http://www.sciencedirect.com/science/article/pii/S004938481400228X
• Kreimann M, Brandt S, Krauel K, et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood. 2014;124(15):2442–9.
  http://www.bloodjournal.org/content/124/15/2442.long 
• Jaax ME, Krauel K, Marschall T, et al. Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood. 2013;122(2):272–81.
  http://www.bloodjournal.org/content/122/2/272.long
• Krauel K, Hackbarth C, Fürll B, et al. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012;119(5):1248–55.
  http://www.bloodjournal.org/content/119/5/1248.long
• Krauel K, Weber C, Brandt S, et al. Platelet factor 4 binding to lipid A of Gram-negative bacteria exposes PF4/heparin-like epitopes. Blood. 2012;120(16):3345–52.
  http://www.bloodjournal.org/content/120/16/3345.long?sso-checked=true
• Kolde H-J, Dostatni R, Mauracher S. Rapid and simple IgG specific test for the exclusion of heparin induced thrombocytopenia (HIT). Clinical Chemistry and Laboratory Medicine. 2011;49(12):2065–8.
  http://www.degruyter.com/view/j/cclm.2011.49.issue-12/cclm.2011.693/cclm.2011.693.xml;jsessionid=51EFD1CF9C16145F6D60E19B3BE38680
• Berthold T, Wesche J, Kuhnert K, et al. Epitope mapping of antibodies directed against the human neutrophil alloantigen 3a. Transfusion. 2011;51(10):2160–7.
  http://onlinelibrary.wiley.com/doi/10.1111/j.1537-2995.2011.03115.x/abstract;jsessionid=2EE008762AF39E9F52BD18B817841F2F.f04t01
• Krauel K, Pӧtschke C, Weber C, et al. Platelet factor 4 binds to bacteria, inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood. 2011;117(4):1370–8.
  http://www.bloodjournal.org/content/117/4/1370.long
• Greinacher A, Holtfreter B, Krauel K, et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood. 2011;118(5):1395–401.
  http://www.bloodjournal.org/content/118/5/1395.long
• Greinacher A, Wesche J, Hammer E, et al. Characterization of the human neutrophil alloantigen-3a. Nature medicine. 2010;16(1):45–8.
  http://www.nature.com/nm/journal/v16/n1/full/nm.2070.html
• Selleng K, Schütt A, Selleng S, et al. Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion. 2010;50(1):32–9.
  http://onlinelibrary.wiley.com/doi/10.1111/j.1537-2995.2009.02360.x/abstract
• Greinacher A, Ittermann T, Bagemühl J, et al. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. Journal of Thrombosis and Haemostasis. 2010;8(9):2025–31.
  http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2010.03974.x/abstract
• Koenen RR, von Hundelshausen P, Nesmelova IV, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nature medicine. 2009;15(1):97–103.
  http://www.nature.com/nm/journal/v15/n1/full/nm.1898.html
• Xiao Z, Visentin GP, Dayananda KM, et al. Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion. Blood. 2008;112(4):1091–100.
  http://www.bloodjournal.org/content/112/4/1091.long
• Krauel K, Fürll B, Warkentin T, et al. Heparin-induced thrombocytopenia-therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. Journal of Thrombosis and Haemostasis. 2008;6(12):2160–7.
  http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2008.03171.x/abstract
• Schenk S, EL-BANAYOSY A, Morshuis M, et al. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. Journal of Thrombosis and Haemostasis. 2007;5(2):235–41.
  http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2007.02295.x/abstract
• Greinacher A, Gopinadhan M, Günther J-U, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(10):2386–93.
  http://atvb.ahajournals.org/content/26/10/2386.long
• Juhl D, Eichler P, Lubenow N, et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. European journal of haematology. 2006;76(5):420–6.
  http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2005.00621.x/abstract
• Von Hundelshausen P, Koenen RR, Sack M, et al. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood. 2005;105(3):924–30.
  http://www.bloodjournal.org/content/105/3/924.long?sso-checked=true

• Schirrmeister J, Zocher S, Flor L, et al. The domain of unknown function DUF1521 exhibits metal ion-inducible autocleavage activity-a novel example from a putative effector protein of Vibrio coralliilyticus ATCC BAA-450. FEMS microbiology letters. 2013;343(2):177–82.
  http://femsle.oxfordjournals.org/content/femsle/343/2/177.full.pdf
• Landgraf P, Sieg F, Wahle P, et al. A maternal blood-borne factor promotes survival of the developing thalamus. The FASEB journal. 2005;19(2):225–7.
  http://www.fasebj.org/content/early/2005/01/27/fj.04-1789fje.long
• Schramm G, Falcone FH, Gronow A, et al. Molecular characterization of an interleukin-4-inducing factor from Schistosoma mansoni eggs. Journal of Biological Chemistry. 2003;278(20):18384–92.
  http://www.jbc.org/content/278/20/18384.long
• Antelmann H, Tjalsma H, Voigt B, et al. A proteomic view on genome-based signal peptide predictions. Genome Research. 2001;11(9):1484–502.
  http://genome.cshlp.org/content/11/9/1484.long

• Cassara M, Menzel V, Hinsch K, et al. Voltage-dependent anion channels 1 and 2 are expressed in porcine oocytes. Bioscience reports. 2010;30:193–200.
  http://www.bioscirep.org/content/30/3/193
• Yiallouros I, Kappelhoff R, Schilling O, et al. Activation mechanism of pro-astacin: role of the pro-peptide, tryptic and autoproteolytic cleavage and importance of precise amino-terminal processing. Journal of molecular biology. 2002;324(2):237–46.
  http://www.sciencedirect.com/science/article/pii/S0022283602011026

• Laux, V.: In Vitro Testing of Twelve Heparinoid Agents on Four Haemostatic Parameters

• US Patent Application 20100093636 - METHODS OF TREATING INFLAMMATION
  Application 20100093636 Filed on October 6, 2009. Published on April 15, 2010
• US 2008/0287652 A1; Nov 20, 2008; PCT/EP2006/00979
  C. Weber, P. v. Hundelshausen, R. Koenen
  Antagonists Against Interaction of PF4 and RANTES

• WO/2007/042263; PCT/EP2006/00979
  C. Weber, P. v. Hundelshausen, R. Koenen
  Antagonistes Utilises Contre L'Interaction de PF4 et de RANTES